813426-13-0

Basic information

• Product Name: 1,2,3,5-tetrahydro-Spiro[4H-1-benzazepine-4,1''-[2]cyclopentene]-3''-carboxylic acid
• Synonyms: 1,2,3,5-tetrahydro-Spiro[4H-1-benzazepine-4,1''-[2]cyclopentene]-3''-carboxylic acid;Spiro[4H-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid, 1,2,3,5-tetrahydro-
• CAS NO: 813426-13-0
• Molecular Formula: C15H17NO2
• Molecular Weight: 243.30098
• Mol File: 813426-13-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 451.81 °C at 760 mmHg
• Flash Point: 227.047 °C
• Appearance: /
• Density: 1.24
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,2,3,5-tetrahydro-Spiro[4H-1-benzazepine-4,1''-[2]cyclopentene]-3''-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,5-tetrahydro-Spiro[4H-1-benzazepine-4,1''-[2]cyclopentene]-3''-carboxylic acid(813426-13-0)
• EPA Substance Registry System: 1,2,3,5-tetrahydro-Spiro[4H-1-benzazepine-4,1''-[2]cyclopentene]-3''-carboxylic acid(813426-13-0)

Safety Data

• Hazardous Substances Data: 813426-13-0(Hazardous Substances Data)

Usage

General Description

1,2,3,5-tetrahydro-Spiro[4H-1-benzazepine-4,1''-[2]cyclopentene]-3''-carboxylic acid, also known as SPIRO, is a chemical compound with a spiro skeleton and a carboxylic acid functional group. It has a molecular formula of C20H22N2O2 and a molar mass of 322.40 g/mol. 1,2,3,5-tetrahydro-Spiro[4H-1-benzazepine-4,1''-[2]cyclopentene]-3''-carboxylic acid has potential biological activities and has been studied for its potential therapeutic applications. Its spiro structure and carboxylic acid group make it a unique and interesting molecule for further research and development.

Upstream product

• 813426-12-9 Ethyl 1,2,3,5-tetrahydro-2'-hydroxy-1-[(4-methylphenyl)sulfonyl]-spiro[4H-1-benzazepine-4,1'-cyclopentane]-3'-carboxylate 

Relevant articles and documents

Novel solid forms of (4R)-1-[2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5- tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid

The present invention relates to novel solid forms of (4R)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4H-1-benzazepine-4,1′-[2]cyclopentene]-3′-carboxylic acid (formula (I)) useful for treating and/or preventing condit

Substituted spirobenzazepines

The invention is directed to nonpeptide substituted benzazepines of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension, among others disclosed. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.